secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001683168-24-005919
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actuate Therapeutics replaces auditor after KMJ joins Crowe; prior reports cite going concern and material weakness
--------------------------------------------------------------------------------

- KMJ Corbin & Company LLP resigned as auditor on Aug 19, 2024; Crowe LLP appointed same day.
- KMJ audit reports for FY2023 and FY2022 included a going-concern explanatory paragraph about substantial doubt.
- Company reported a material weakness in internal control over financial reporting due to inadequate review of clinical trial expense accruals.
- No disagreements between Company and KMJ on accounting principles or auditing scope.
- KMJ's professional staff joined Crowe LLP on May 20, 2024; change is related to that merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316824005919/0001683168-24-005919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316824005919/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer